Full-Time
Develops and commercializes biologic drugs
$140k - $150k/yr
Seattle, WA, USA
In Person
| , |
Lumen Bioscience develops and commercializes biologic drugs using a patented production platform that makes drug development faster, cheaper, and scalable. Biologic drugs are therapeutic proteins produced from living cells, and Lumen Bio uses its technology to manufacture these biologics more efficiently and at a lower cost, enabling broader access for patients. The company’s products are designed to treat conditions like inflammatory bowel disease and metabolic diseases, and it serves hospitals, healthcare providers, and patients. Unlike traditional biopharma methods that can be slow and expensive, Lumen Bio focuses on scaling production and reducing development time to offer more affordable biologics. Its goal is to bring safe and effective biologic therapies to a wider patient population, address neglected health issues, and improve outcomes for diseases with high unmet need.
Company Size
51-200
Company Stage
Series C
Total Funding
$167.6M
Headquarters
Seattle, Washington
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
People at Lumen Bioscience who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Unlimited Paid Time Off
Monthly Wellness Program
Free onsite parking or public transportation subsidies
Comprehensive parental leave policies
Life Insurance
Short & Long-Term Disability
Fresh off $30M round, seattle startup Lumen Bioscience adds Microsoft vet Jeff Raikes to board. Seattle-based biotech startup Lumen Bioscience raised a $30 million Series C extension and announced several leadership updates. WestRiver Group led the latest funding round, bringing the company's total capital raised to $186.8 million. The new investment will help Lumen accelerate its pipeline of orally delivered biologic drugs made from genetically engineered spirulina, a type of blue-green algae. Lumen's technology platform enables therapeutic proteins - traditionally injected or infused - to be produced and delivered orally in an edible, low-cost form. The 110-person company is targeting diseases that act in or originate from the gastrointestinal tract. It recently reported promising Phase 2 results from LMN-201, Lumen's lead candidate for recurrent C. difficile infection. The company also announced that Jeff Raikes, former Microsoft president and Gates Foundation CEO, joined Lumen's board as an independent director. * Erik Anderson, founder and CEO of WestRiver Group, was elected vice chairman of the board. * Internal promotions include Nhi Khuong to EVP and Kole Krieger to SVP, while Dr. David Saunders, a retired U.S. Army colonel and clinical trialist, joined the clinical development team. The company has grown its workforce by nearly 40% since 2023 and opened a second manufacturing facility. Lumen is led by CEO Brian Finrow, a former senior vice president at Adaptive Biotechnologies, and Chief Science Officer Jim Roberts, the former head of basic sciences at the Fred Hutchinson Cancer Research Institute. They co-founded the startup in 2017.
Lumen Bioscience has expanded its board and leadership team following a $30 million Series C financing extension led by WestRiver Group, with participation from the Gates Foundation and others. Jeff Raikes joins as an independent director, while Nhi Khuong and Kole Krieger receive promotions. David Saunders joins the clinical team. The funding will accelerate late-stage clinical programs and commercial readiness, with a focus on spirulina-based GMP manufacturing for oral biologics.
Opyl's Opin secures patient recruitment contract for US-based Lumen Bioscience.
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.
SEATTLE, Oct. 17, 2023 /PRNewswire/ -- Lumen Bioscience -a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced it was awarded $16.2 million by the U.S. Department of Defense to advance LMN-201 through late-stage trials.